Back to today’s briefing

Story perspectives

Biotech Innovations Surge: Luvelta and Tri-Specific Antibody Breakthroughs

1/12/2025

45 4

Summary

Story summary

The biotech landscape in 2025 is buzzing with innovation, as major players make strides in large molecule and advanced therapies. Boehringer Ingelheim is ramping up luvelta production in Austria, while Bora Biologics is crafting a groundbreaking tri-specific antibody in Taiwan. Meanwhile, Viralgen teams up with MIT to push the boundaries of gene therapy, showcasing the vital role of CDMOs in driving clinical progress.

1 of 1

Story summary

The biotech landscape in 2025 is buzzing with innovation, as major players make strides in large molecule and advanced therapies. Boehringer Ingelheim is ramping up luvelta production in Austria, while Bora Biologics is crafting a groundbreaking tri-specific antibody in Taiwan. Meanwhile, Viralgen teams up with MIT to push the boundaries of gene therapy, showcasing the vital role of CDMOs in driving clinical progress.